AU777542B2 - Use of Apo B secretion/MTP inhibitors - Google Patents

Use of Apo B secretion/MTP inhibitors Download PDF

Info

Publication number
AU777542B2
AU777542B2 AU71519/00A AU7151900A AU777542B2 AU 777542 B2 AU777542 B2 AU 777542B2 AU 71519/00 A AU71519/00 A AU 71519/00A AU 7151900 A AU7151900 A AU 7151900A AU 777542 B2 AU777542 B2 AU 777542B2
Authority
AU
Australia
Prior art keywords
phenyl
ring
alkoxy
hydroxy
compound
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU71519/00A
Other languages
English (en)
Other versions
AU7151900A (en
Inventor
Mary Anne Hickman
Kristin Marie Lundy
Bradley Paul Morgan
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pfizer Products Inc
Original Assignee
Pfizer Products Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Products Inc filed Critical Pfizer Products Inc
Publication of AU7151900A publication Critical patent/AU7151900A/en
Application granted granted Critical
Publication of AU777542B2 publication Critical patent/AU777542B2/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4468—Non condensed piperidines, e.g. piperocaine having a nitrogen directly attached in position 4, e.g. clebopride, fentanyl
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/472—Non-condensed isoquinolines, e.g. papaverine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Obesity (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Child & Adolescent Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Other In-Based Heterocyclic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Plural Heterocyclic Compounds (AREA)
AU71519/00A 1999-11-10 2000-11-09 Use of Apo B secretion/MTP inhibitors Ceased AU777542B2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US16451399P 1999-11-10 1999-11-10
US60/164513 1999-11-10

Publications (2)

Publication Number Publication Date
AU7151900A AU7151900A (en) 2001-05-17
AU777542B2 true AU777542B2 (en) 2004-10-21

Family

ID=22594839

Family Applications (1)

Application Number Title Priority Date Filing Date
AU71519/00A Ceased AU777542B2 (en) 1999-11-10 2000-11-09 Use of Apo B secretion/MTP inhibitors

Country Status (11)

Country Link
EP (1) EP1099438A3 (enExample)
JP (1) JP2001181209A (enExample)
KR (1) KR100439384B1 (enExample)
AU (1) AU777542B2 (enExample)
CA (1) CA2325282C (enExample)
CO (1) CO5271688A1 (enExample)
HU (1) HUP0004454A3 (enExample)
IL (1) IL139449A0 (enExample)
NZ (1) NZ508061A (enExample)
PE (1) PE20010679A1 (enExample)
ZA (1) ZA200006417B (enExample)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6825209B2 (en) 2002-04-15 2004-11-30 Research Triangle Institute Compounds having unique CB1 receptor binding selectivity and methods for their production and use
KR100799802B1 (ko) 2004-02-04 2008-01-31 화이자 프로덕츠 인크. 치환된 퀴놀린 화합물
WO2006129193A2 (en) * 2005-05-27 2006-12-07 Pfizer Products Inc. Combination of a cannabinoid-1- receptor-antagonist and a microsomal triglyceride transfer protein inhibitor for treating obesity or mainataining weight loss
WO2008090198A1 (en) * 2007-01-25 2008-07-31 Janssen Pharmaceutica Nv Use of mtp inhibitors for increasing levels of satiety hormones
HUE049261T2 (hu) 2014-07-15 2020-09-28 Yissum Research And Development Company Of The Hebrew Univ Of Jerusalem Ltd CD44 izolált polipeptidek és alkalmazásaik

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996040640A1 (en) * 1995-06-07 1996-12-19 Pfizer Inc. BIPHENYL-2-CARBOXYLIC ACID-TETRAHYDRO-ISOQUINOLIN-6-YL AMIDE DERIVATIVES, THEIR PREPARATION AND THEIR USE AS INHIBITORS OF MICROSOMAL TRIGLYCERIDE TRANSFER PROTEIN AND/OR APOLIPOPROTEIN B (Apo B) SECRETION
EP0887345A1 (en) * 1997-06-23 1998-12-30 Pfizer Inc. 4'-trifluoromethylbiphenyl-2-carboxylic acid-[2-(2-acetylaminoethyl)-1,2,3,4-tetrahydroisoquinolin-6-yl]amide hydrochloride as apo B-secretion/MTP inhibitors

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1992018132A1 (en) * 1991-04-17 1992-10-29 Merck & Co., Inc. Pharmaceutical combination for the treatment of benign prostatic hyperplasia comtaining a 5 alpha-reductase inhibitor
US5474993A (en) * 1994-06-14 1995-12-12 Sterling Winthrop, Inc. Lactam inhibitors of cholesterol esterase
DK0902785T3 (da) * 1996-04-30 2002-10-07 Pfizer Fremgangsmåder og mellemprodukter til fremstilling af 4'-trifluormethylbiphenyl-2-carboxylsyre-[2-(2H-[1,2,4]triazol-3-ylmethyl)-1,2,3,4-tetrahydroisoquinolin-2-yl]amid
US5883109A (en) * 1996-07-24 1999-03-16 Bristol-Myers Squibb Company Method for lowering serum lipid levels employing an MTP inhibitor in combination with another cholesterol lowering drug
TR199901180T2 (xx) * 1996-11-27 1999-08-23 Pfizer Inc. Apo B-Salg�lama/MTP inhibit�r amidler.
IL133201A0 (en) * 1998-12-04 2001-03-19 Pfizer Prod Inc Lowering blood levels of lipoproten (a)

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996040640A1 (en) * 1995-06-07 1996-12-19 Pfizer Inc. BIPHENYL-2-CARBOXYLIC ACID-TETRAHYDRO-ISOQUINOLIN-6-YL AMIDE DERIVATIVES, THEIR PREPARATION AND THEIR USE AS INHIBITORS OF MICROSOMAL TRIGLYCERIDE TRANSFER PROTEIN AND/OR APOLIPOPROTEIN B (Apo B) SECRETION
EP0887345A1 (en) * 1997-06-23 1998-12-30 Pfizer Inc. 4'-trifluoromethylbiphenyl-2-carboxylic acid-[2-(2-acetylaminoethyl)-1,2,3,4-tetrahydroisoquinolin-6-yl]amide hydrochloride as apo B-secretion/MTP inhibitors

Also Published As

Publication number Publication date
CA2325282C (en) 2005-12-06
KR100439384B1 (ko) 2004-07-09
CA2325282A1 (en) 2001-05-10
HUP0004454A2 (hu) 2001-10-28
KR20010051509A (ko) 2001-06-25
EP1099438A3 (en) 2003-03-19
ZA200006417B (en) 2002-05-08
IL139449A0 (en) 2001-11-25
HU0004454D0 (enExample) 2001-01-29
AU7151900A (en) 2001-05-17
JP2001181209A (ja) 2001-07-03
HUP0004454A3 (en) 2004-04-28
CO5271688A1 (es) 2003-04-30
PE20010679A1 (es) 2001-06-30
EP1099438A2 (en) 2001-05-16
NZ508061A (en) 2002-04-26

Similar Documents

Publication Publication Date Title
TWI331525B (en) Combinations comprising an antidiarrheal agent and an epothilone or an epothilone derivative
ES2379419T3 (es) Usos terapéuticos de compuestos que tienen actividad SERT, 5-HT3 y 5-HT1A combinada
KR20010006712A (ko) 갑상선 호르몬 유사 효과의 비만 치료제
BG65996B1 (bg) Състав, съдържащ трамадолово производно и антиконвулсантно лекарствено средство
BRPI0712360A2 (pt) método para intensificação de função cognitiva
EP2275138A1 (en) Promoter for bicarbonate secretion in gastrointestinal tract
JP2015523382A (ja) メトホルミンの三塩形態
BR112019022902A2 (pt) composição, composição farmacêutica, uso da composição terapeuticamente eficaz, método e uso de uma composição terapeuticamente eficaz em um método de tratamento
JP2015131865A (ja) 抗癌用医薬
US3060091A (en) Analgesic composition consisting of morphines and amino-indanes
CA2325201A1 (en) Methods of administering apo b-secretion/mtp inhibitors
ES2385087T3 (es) Procedimientos para tratar trastornos relacionados con sustancias
EP1099441A2 (en) Compositions containing apo B secretion/MTP inhibitors and anti-obesity agents and use thereof
BRPI0615046A2 (pt) uso de um composto, e, formulação para administração oral
CA2324800A1 (en) Use of apo b secretion/mtp inhibitors
AU7151900A (en) Use of Apo B secretion/MTP inhibitors
Gruen et al. Drugs affecting animal behavior
Hough et al. Antinociceptive activity of furan-containing congeners of improgan and ranitidine
RU2009149637A (ru) Композиции, применимые для лечения гастроэзофагеальной рефлюксной болезни
RU2341260C2 (ru) Комбинации, включающие производные эпотилона и алкилирующие агенты
RU99118510A (ru) Композиция для лечения или предупреждения рака простаты
JP6714225B2 (ja) 肝細胞癌の予防又は治療のための医薬
EP2353594A1 (en) Compositions comprising tramadol and the co-crystal of celecoxib and L-proline in the treatment of pain
BR112019021140A2 (pt) composição, método para reduzir os níveis de glicose no sangue, ganho de peso ou níveis de depósito de gordura, ou tratamento, método de indução do bege de adipócitos ou prevenção da degeneração das células beta do pâncreas, e, ativador de lyn cinase e agonista de trpm8 para uso na redução dos níveis de glicose no sangue, ganho de peso ou níveis de depósito de gordura, ou tratamento.
TH40574A (th) อนุพันธ์ของไฮดรอกซีคิวมาราโนนที่ถูกแทนที่ที่ 0 ในฐานะที่เป็นสารต่อต้านเนื้องอกและต่อต้านการแพร่กระจายเซลเนื้อร้าย